Vanguard Personalized Indexing Management LLC Sells 152 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Vanguard Personalized Indexing Management LLC reduced its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 8.1% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 1,731 shares of the medical research company’s stock after selling 152 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Bio-Rad Laboratories were worth $473,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Dimensional Fund Advisors LP raised its stake in Bio-Rad Laboratories by 64.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 494,604 shares of the medical research company’s stock valued at $135,081,000 after acquiring an additional 193,700 shares during the period. Massachusetts Financial Services Co. MA lifted its position in Bio-Rad Laboratories by 0.4% during the second quarter. Massachusetts Financial Services Co. MA now owns 348,540 shares of the medical research company’s stock worth $95,190,000 after acquiring an additional 1,288 shares during the last quarter. Thompson Siegel & Walmsley LLC lifted its position in Bio-Rad Laboratories by 11.4% during the second quarter. Thompson Siegel & Walmsley LLC now owns 390,020 shares of the medical research company’s stock worth $106,518,000 after acquiring an additional 40,006 shares during the last quarter. Envestnet Asset Management Inc. boosted its holdings in shares of Bio-Rad Laboratories by 9.2% during the second quarter. Envestnet Asset Management Inc. now owns 109,051 shares of the medical research company’s stock worth $29,783,000 after acquiring an additional 9,185 shares during the period. Finally, Oppenheimer Asset Management Inc. grew its position in shares of Bio-Rad Laboratories by 19.6% in the second quarter. Oppenheimer Asset Management Inc. now owns 2,719 shares of the medical research company’s stock valued at $743,000 after purchasing an additional 446 shares during the last quarter. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Performance

NYSE BIO opened at $331.71 on Friday. The firm’s fifty day moving average price is $325.80 and its two-hundred day moving average price is $307.44. The stock has a market cap of $9.46 billion, a PE ratio of -32.02 and a beta of 0.95. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 6.28. Bio-Rad Laboratories, Inc. has a fifty-two week low of $261.59 and a fifty-two week high of $366.30.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings data on Thursday, August 1st. The medical research company reported $3.11 earnings per share for the quarter, topping analysts’ consensus estimates of $2.12 by $0.99. Bio-Rad Laboratories had a positive return on equity of 3.77% and a negative net margin of 51.73%. The business had revenue of $638.50 million for the quarter, compared to analyst estimates of $645.79 million. During the same quarter in the previous year, the company posted $3.00 EPS. Bio-Rad Laboratories’s quarterly revenue was down 6.3% compared to the same quarter last year. On average, equities analysts expect that Bio-Rad Laboratories, Inc. will post 10.31 EPS for the current fiscal year.

Insider Transactions at Bio-Rad Laboratories

In related news, EVP James Barry sold 623 shares of Bio-Rad Laboratories stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total transaction of $205,895.27. Following the sale, the executive vice president now directly owns 147 shares in the company, valued at approximately $48,582.03. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Bio-Rad Laboratories news, EVP James Barry sold 623 shares of the company’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total value of $205,895.27. Following the sale, the executive vice president now owns 147 shares in the company, valued at approximately $48,582.03. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Andrew J. Last sold 3,000 shares of the company’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $329.94, for a total transaction of $989,820.00. Following the completion of the sale, the chief operating officer now directly owns 7,559 shares in the company, valued at $2,494,016.46. The disclosure for this sale can be found here. Company insiders own 17.06% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on BIO. Wells Fargo & Company started coverage on shares of Bio-Rad Laboratories in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 target price on the stock. Jefferies Financial Group reaffirmed a “hold” rating and issued a $315.00 price target (down previously from $440.00) on shares of Bio-Rad Laboratories in a research note on Monday, June 3rd. Royal Bank of Canada reissued an “outperform” rating and issued a $401.00 target price on shares of Bio-Rad Laboratories in a report on Friday, August 16th. StockNews.com cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Citigroup boosted their price target on Bio-Rad Laboratories from $300.00 to $350.00 and gave the stock a “neutral” rating in a report on Friday, August 2nd. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $358.20.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.